Shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) have received an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $3.35.
A number of analysts have issued reports on NVCN shares. Zacks Investment Research raised Neovasc Inc (US) from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Wednesday, October 11th. ValuEngine downgraded Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Canaccord Genuity reissued a “buy” rating and issued a $1.05 target price on shares of Neovasc Inc (US) in a research report on Friday.
A hedge fund recently raised its stake in Neovasc Inc (US) stock. Capital World Investors lifted its stake in Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) by 9.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,294,667 shares of the medical equipment provider’s stock after acquiring an additional 522,864 shares during the period. Capital World Investors owned approximately 7.98% of Neovasc Inc (US) worth $8,737,000 at the end of the most recent reporting period. 19.04% of the stock is owned by institutional investors.
Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last released its earnings results on Tuesday, November 14th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a negative return on equity of 85.81% and a net margin of 268.35%. equities analysts forecast that Neovasc Inc will post -0.21 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Neovasc Inc (US) (NVCN) Receives $4.50 Consensus Price Target from Brokerages” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/22/neovasc-inc-us-nvcn-receives-4-50-consensus-price-target-from-brokerages.html.
About Neovasc Inc (US)
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.